New Two-Drug attack on Tough-to-Treat lung cancer
NCT ID NCT05815173
Summary
This study is testing whether adding a new oral drug called ladarixin to an existing lung cancer drug (sotorasib) is safe and effective for people with advanced lung cancer that has a specific KRAS G12C mutation. The first part of the study will find the safest dose of the combination, and the second part will measure how long patients live without their cancer getting worse. It is for adults whose cancer has progressed after standard immunotherapy and chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGGarden City, New York, 11530, United States
-
NYU Langone Health
RECRUITINGMineola, New York, 11501, United States
-
NYU Langone Health
RECRUITINGNew Hyde Park, New York, 11042, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10010, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10017, United States
Conditions
Explore the condition pages connected to this study.